Is herein described a nanoparticle ophthalmic composition comprising at least 0.1% of Perilla frutescens extract and at least 0.1% of hyaluronic acid or a salt thereof wherein the Perilla frutescens extract has a content of polyphenols of at least 2.5% by weight of the total weight of the extract and to the use of said ophthalmic composition in the treatment of ocular disorders or diseases such as tear dysfunction syndrome, dry eye, diabetic retinopathy and glaucoma, preferably in the treatment of tear dysfunction syndrome.

A pharmaceutical composition for preventing and treating cancer of reproductive system and preparation method therefor. The pharmaceutical composition is prepared using one or more of the following as raw material: pinellia tuber, bighead atractylodes rhizome, gastralia tuber, liquorice root, Indian bread, white peony root, fresh ginger.

A pharmaceutical composition for preventing and treating cancer of reproductive system and preparation method therefor. The pharmaceutical composition is prepared using one or more of the following as raw material: pinellia tuber, bighead atractylodes rhizome, gastralia tuber, liquorice root, Indian bread, white peony root, fresh ginger.

Provided is a method for producing a red perilla leaf extract which enables to collect rosmarinic acid with a high yield from red perilla leaves to which an acid is added. The method for producing a red perilla leaf extract includes the following step (1): (1) a step of extracting red perilla leaves to which an acid has been added with water under a condition of a pH of from 4.0 to 8.0.

Provided is a method for producing a red perilla leaf extract which enables to collect rosmarinic acid with a high yield from red perilla leaves to which an acid is added. The method for producing a red perilla leaf extract includes the following step (1): (1) a step of extracting red perilla leaves to which an acid has been added with water under a condition of a pH of from 4.0 to 8.0.

In accordance with a non-limiting example, an algae based oil is used in place of a krill oil to treat low density lipoprotein (LDL) oxidation in humans by administering a therapeutic amount of a dietary supplement composition comprising an algae based oil comprising glycolipids and phospholipids and Eicosapentaenoic (EPA) fatty acids in combination with astaxanthin derived from Haematococcus pluvialis (Hp) in an oral dosage form, wherein the astaxanthin derived from Haematococcus pluvialis (Hp) is 0.1 to 4.0 percent by weight of the algae based oil.

In accordance with a non-limiting example, an algae based oil is used in place of a krill oil to treat low density lipoprotein (LDL) oxidation in humans by administering a therapeutic amount of a dietary supplement composition comprising an algae based oil comprising glycolipids and phospholipids and Eicosapentaenoic (EPA) fatty acids in combination with astaxanthin derived from Haematococcus pluvialis (Hp) in an oral dosage form, wherein the astaxanthin derived from Haematococcus pluvialis (Hp) is 0.1 to 4.0 percent by weight of the algae based oil.

A composition of matter comprises a shelf stable, partially defatted supercritical CO.sup.2 fluid solvent extracted whole grain flour derived from a cracked biomass of perilla frutescens, the flour comprising minerals and 2 to 8 percent of native seed oil, 35 to 45 percent protein, and 35 to 45 percent fiber.

A composition of matter comprises a shelf stable, partially defatted supercritical CO.sup.2 fluid solvent extracted whole grain flour derived from a cracked biomass of perilla frutescens, the flour comprising minerals and 2 to 8 percent of native seed oil, 35 to 45 percent protein, and 35 to 45 percent fiber.

A dietary supplement includes comprising a therapeutic amount of astaxanthin derived from a synthetic or natural ester or diol, and at least one of a phospholipid, glycolipid, and sphingolipid, and formulated into an oral dosage form, wherein the astaxanthin is 0.1 to 15 percent by weight of the at least one phospholipid, glycolipid, and sphingolipid. The composition includes 0.5 to 12 mg of astaxanthin and may be used to treat low density lipoprotein (LDL) oxidation in humans and other diseases, disorders and impairments.